트리메토프림/설파디아진 및 트리메토프림/설파메톡사졸

용도

• UTI
• UTI, soft tissue infections
• Susceptible infections
• Toxoplasmosis
• Bacterial UTI
• Susceptible infections
• Coccidiosis
• Susceptible infections
• Susceptible infections
• Susceptible infections (Calves)
• Respiratory tract infections
• Susceptible infections (Foals)
• Susceptible infections
• Susceptible infections

투여 방법

가능한 부작용

• Dogs: Keratoconjunctivitis sicca (KCS/dry eye - potentially irreversible)
• Dogs: Hypersensitivity reactions (Type 1 anaphylaxis or Type 3 serum sickness, polyarthritis, urticaria, facial swelling)
• Dogs: Acute neutrophilic hepatitis with icterus, idiosyncratic hepatic necrosis
• Dogs: Vomiting, anorexia, diarrhea
• Dogs: Hemolytic anemia, agranulocytosis
• Dogs: Hypothyroidism (with extended therapy)
• Dogs: Crystalluria, hematuria, polyuria, polydipsia
• Cats: Anorexia, crystalluria, hematuria, leukopenias, anemias
• Horses: Transient pruritus (after IV injection), diarrhea, hypersensitivity, hematologic effects
• Injection site reactions: Swelling, pain, tissue damage (IM, SC, or extravasation)

주의사항 및 금기

• Hypersensitivity to sulfonamides, thiazides, or sulfonylurea agents
• Severe renal or hepatic impairment
• Doberman pinschers (highly susceptible to immune complex disease)
• Marked blood dyscrasias
• Animals intended for food (in the USA/certain jurisdictions)
• Use with caution in patients with pre-existing hepatic or renal disease. Because of its potential for crystallization in the urine, avoid use in dogs known to have uroliths, at increased risk for developing uroliths, or those with highly concentrated (dehydrated) or acidic urine. Potentially teratogenic (cleft palate reported); weigh risk vs. benefit in pregnant animals. Use with caution in nursing animals as sulfonamides are excreted in milk and may cause kernicterus in neonates.

약물 상호작용

• Amantadine: May cause toxic delirium (reported in humans)
• Antacids: May decrease the bioavailability of sulfonamides if administered concurrently
• Cyclosporine: May increase the risk of nephrotoxicity
• Digoxin: May increase digoxin levels
• Diuretics, Thiazide: May increase risk for thrombocytopenia
• Hypoglycemic agents, oral: May potentiate hypoglycemic effects
• Methotrexate: May displace from plasma proteins and increase risk for toxic effects; can also interfere with MTX assays
• Phenytoin: May increase half-life of phenytoin
• Tricyclic antidepressants: May decrease efficacy of the antidepressant
• Warfarin: May prolong INR/PT and increase bleeding risk

자주 묻는 질문